Dzau VJ, Bernstein K, Celermajer D, Cohen J, Dahlof B, Deanfield J, Diez J, Drexler H, Ferrari R, van Gilst W: The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. The American journal of cardiology. 2001, 88 (9A): 1L-20L. 10.1016/S0002-9149(01)01878-1.
Article
CAS
PubMed
Google Scholar
Jacobsen PK: Preventing end-stage renal disease in diabetic patients – dual blockade of the renin-angiotensin system (Part II). J Renin Angiotensin Aldosterone Syst. 2005, 6 (2): 55-68. 10.3317/jraas.2005.011.
Article
CAS
PubMed
Google Scholar
Jacobsen PK: Preventing end stage renal disease in diabetic patients – genetic aspect (part I). J Renin Angiotensin Aldosterone Syst. 2005, 6 (1): 1-14. 10.3317/jraas.2005.001.
Article
CAS
PubMed
Google Scholar
Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer?. Lancet. 1998, 352 (9123): 179-184. 10.1016/S0140-6736(98)03228-0.
Article
CAS
PubMed
Google Scholar
Koh WP, Yuan JM, Sun CL, Berg van den D, Seow A, Lee HP, Yu MC: Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res. 2003, 63 (3): 573-578.
CAS
PubMed
Google Scholar
Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med. 2001, 111 (8): 633-642. 10.1016/S0002-9343(01)00978-0.
Article
CAS
PubMed
Google Scholar
Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation. 1994, 90 (4): 2056-2069.
Article
CAS
PubMed
Google Scholar
Sleight P: Angiotensin II and trials of cardiovascular outcomes. The American journal of cardiology. 2002, 89 (2A): 11A-16A. 10.1016/S0002-9149(01)02322-0.
Article
CAS
PubMed
Google Scholar
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000, 342 (3): 145-153. 10.1056/NEJM200001203420301.
Article
CAS
PubMed
Google Scholar
Solski LV, Longyhore DS: Prevention of type 2 diabetes mellitus with angiotensin-converting-enzyme inhibitors. Am J Health Syst Pharm. 2008, 65 (10): 935-940. 10.2146/ajhp070388.
Article
CAS
PubMed
Google Scholar
MacLean CD, Littenberg B, Gagnon M, Reardon M, Turner PD, Jordan C: The Vermont Diabetes Information System (VDIS): study design and subject recruitment for a cluster randomized trial of a decision support system in a regional sample of primary care practices. Clin Trials. 2004, 1 (6): 532-544. 10.1191/1740774504cn051oa.
Article
PubMed
PubMed Central
Google Scholar
Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN: The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum. 2003, 49 (2): 156-163. 10.1002/art.10993.
Article
PubMed
Google Scholar
Tamborlane WV, Kollman C, Steffes MW, Ruedy KJ, Dongyuan X, Beck RW, Chase P, Fox LA, Wilson DM, Tsalikian E: Comparison of fingerstick hemoglobin A1c levels assayed by DCA 2000 with the DCCT/EDIC central laboratory assay: results of a Diabetes Research in Children Network (DirecNet) Study. Pediatr Diabetes. 2005, 6 (1): 13-16. 10.1111/j.1399-543X.2005.00088.x.
Article
PubMed
Google Scholar
MacLean CD, Littenberg B, Kennedy AG: Limitations of diabetes pharmacotherapy: results from the Vermont Diabetes Information System study. BMC Fam Pract. 2006, 7: 50-10.1186/1471-2296-7-50.
Article
PubMed
PubMed Central
Google Scholar
Ramos-Nino ME, MacLean CD, Littenberg B: Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC medicine. 2007, 5: 17-10.1186/1741-7015-5-17.
Article
PubMed
PubMed Central
Google Scholar
Small W, Molteni A, Kim YT, Taylor JM, Ts'ao CH, Ward WF: Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. Breast Cancer Res Treat. 1999, 55 (3): 223-229. 10.1023/A:1006233521325.
Article
CAS
PubMed
Google Scholar
Fernandez LA, Twickler J, Mead A: Neovascularization produced by angiotensin II. J Lab Clin Med. 1985, 105 (2): 141-145.
CAS
PubMed
Google Scholar
Sadoshima J, Aoki H, Izumo S: Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. Circ Res. 1997, 80 (2): 228-241.
Article
CAS
PubMed
Google Scholar
Molteni A, Ward WF, Ts'ao CH, Taylor J, Small W, Brizio-Molteni L, Veno PA: Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Current pharmaceutical design. 2003, 9 (9): 751-761. 10.2174/1381612033455396.
Article
CAS
PubMed
Google Scholar
Small W, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF: Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast cancer research and treatment. 1997, 44 (3): 217-224. 10.1023/A:1005827119296.
Article
CAS
PubMed
Google Scholar
Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR: Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer. 1998, 77 (6): 880-883.
Article
CAS
PubMed
PubMed Central
Google Scholar
Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP: Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996, 98 (3): 671-679. 10.1172/JCI118838.
Article
CAS
PubMed
PubMed Central
Google Scholar
Rao SP, Sathiamoorthy A, Sathiamoorthy SS: Effect of angiotensin converting enzyme inhibitor (captopril) on gastric ulcer production in pylorus ligated rats. Indian J Physiol Pharmacol. 1995, 39 (3): 296-298.
CAS
PubMed
Google Scholar
Uluoglu C, Guney Z, Kilinc M, Bozkurt S, Ercan ZS: The effects of captopril and naloxone on restraint-cold-stress- and ethanol-induced gastric lesions in rats. General pharmacology. 1998, 30 (5): 701-704. 10.1016/S0306-3623(97)00375-3.
Article
CAS
PubMed
Google Scholar
Mou D, Zhu X, Xu W, Du R: The pathogenetic role of endogenous angiotensin II in stress ulcer in obstructive jaundice rats. Chin Med J (Engl). 1998, 111 (4): 309-312.
CAS
Google Scholar
Iakubov AV, Usmanova Sh E: [Prophylactic use of angiotensin-converting enzyme inhibitors in indomethacin-induced ulcer and erosion lesions of the stomach]. Likars'ka sprava/Ministerstvo okhorony zdorov'ia Ukrainy. 2004, 47-49. 2
Sugimoto M, Furuta T, Shirai N, Ikuma M, Sugimura H, Hishida A: Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol Biomarkers Prev. 2006, 15 (10): 1929-1934. 10.1158/1055-9965.EPI-06-0339.
Article
CAS
PubMed
Google Scholar